DELAVAL
ActiveSummary
DELAVAL has been active since 1985 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €2.4m and a net result of €1.2m. Equity is growing by ~21.1% per year across the filed fiscal years. Its solvency ranks better than 15% of 68 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).
Checked score
Score 2025
Axes · tick = 2024
Profitability66▼-1
Solvency40▼-2
Growth71▲+1
Track record100
Bankruptcy probability, 12 months
0.3%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €130,000 at 30 days acceptable
Liquidity tight (current ratio 1.13 against 1.0 in 2024; short-term debt: 73.5% and cash: 2.5% of total assets), and 85.2% of the assets are financed with debt.
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
Seven signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
14.8%
Return on assets
7.3%
Age of the figures
9 mo
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 21
Relative position
BE, all sectors
reference
Manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21)
about 14% more bankruptcies
← fewer bankruptcies
more bankruptcies →
raises risk · Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 15% of 68 sector peers (2025).
NBB · sector comparisonPosition among 68 sector peers
Solvency
better than 15%
← weakest
strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 10-07-2026, 21 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
21 d early
2024
36 d early
2023
57 d early
2022
76 d early
2021
74 d early
2020
72 d early
2019
58 d early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 7 accounts on average 56 days before the deadline; the sector median for financial year 2024 is 9 days before the deadline, and 32% of the sector filed late.
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. Usually files around 5 June (4 of the last 5 filed years within 30 days of that day).
Companies Code · seven monthsPosition in the running window
29-09-2026 today31-12-2026 close31-07-2027 deadline
History
Go further with this company
How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Is the workforce growing, and do people stay?Employer check Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check What other support did companies like this one receive, and it did not?Public money
Is this your company? See how customers and banks see it.
Investigating this company? Keep it with today's facts in a case file.
Financials · fiscal year 2025, full schema
In the rankings
#4 company by total assets in East Flanders, Pharmaceuticals sector#5 oldest company in East Flanders, Pharmaceuticals sector#7 company by equity in East Flanders, Pharmaceuticals sector
Turnover
€43.4m▲ 8.8%
2024 · €39.9m
EBIT margin
4.3%▲ 0.1pp
2024 · 4.3%
Net result
€1.2m▲ 11.9%
2024 · €1.0m
Working capital
€1.5m
2024 · -€13,124
Trend over the years
Click a name to add, emphasise or remove a line.Band: the middle half (P25 to P75) of NACE 21, Manufacture of basic pharmaceutical products and pharmaceutical preparations, each year against the same schema; no band under 30 filings. Dashed line: the median.
Every figure with its change against the fiscal year before
favourable
unfavourable
Line20212022202320242025
Turnover€32.9m▲ 6.1%€36.1m▲ 9.9%€42.1m▲ 16.5%€39.9m▼ 5.2%€43.4m▲ 8.8%
Operating result€1.4m▲ 29.0%€1.3m▼ 11.3%€2.2m▲ 72.7%€1.7m▼ 23.4%€1.9m▲ 10.1%
Net result€943,907within the sector's middle half▲ 22.3%€787,159within the sector's middle half▼ 16.6%€1.4mwithin the sector's middle half▲ 74.5%€1.0mwithin the sector's middle half▼ 24.1%€1.2mwithin the sector's middle half▲ 11.9%
EBIT margin4.4%▲ 0.8pp3.6%▼ 0.9pp5.3%▲ 1.7pp4.3%▼ 1.0pp4.3%▲ 0.1pp
Equity€993,186within the sector's middle half▲ 4.6%€1.3mwithin the sector's middle half▲ 28.9%€1.9mwithin the sector's middle half▲ 48.7%€2.2mwithin the sector's middle half▲ 15.3%€2.4mwithin the sector's middle half▲ 7.6%
Total assets€11.1mwithin the sector's middle half▲ 2.6%€14.2mwithin the sector's middle half▲ 28.6%€15.7mwithin the sector's middle half▲ 10.6%€13.1mwithin the sector's middle half▼ 16.6%€16.0mwithin the sector's middle half▲ 21.9%
Debt€9.4m▲ 8.8%€12.6m▲ 33.8%€13.4m▲ 6.1%€10.3m▼ 23.2%€12.7m▲ 23.8%
Working capital-€845,855below the sector's middle half▼ 35.8%-€899,987below the sector's middle half▼ 6.4%-€563,529below the sector's middle half▲ 37.4%-€13,124within the sector's middle half▲ 97.7%€1.5mwithin the sector's middle half
Solvency9.0%below the sector's middle half▲ 0.2pp9.0%below the sector's middle half=12.1%below the sector's middle half▲ 3.1pp16.7%below the sector's middle half▲ 4.6pp14.8%below the sector's middle half▼ 2.0pp
Current ratio0.91below the sector's middle half▼ 0.020.92below the sector's middle half▲ 0.020.96below the sector's middle half▲ 0.031.00within the sector's middle half▲ 0.041.13below the sector's middle half▲ 0.13
Return on assets (ROA)8.5%above the sector's middle half▲ 1.4pp5.5%within the sector's middle half▼ 3.0pp8.7%above the sector's middle half▲ 3.2pp7.9%within the sector's middle half▼ 0.8pp7.3%within the sector's middle half▼ 0.6pp
Staff (FTE)60.4within the sector's middle half▲ 4.0%58.5within the sector's middle half▼ 3.1%61.5within the sector's middle half▲ 5.1%58.9within the sector's middle half▼ 4.2%65.5within the sector's middle half▲ 11.2%
above
within
below
the middle half (P25 to P75) of NACE 21, Manufacture of basic pharmaceutical products and pharmaceutical preparations, each year against the same schema; no band under 30 filings.
Result per fiscal year
Operating resultNet result
The operating result recovers in 2025; 2025 is 10% above 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €16.0m
Fixed assets
€2.7m ▼ 18.3%
Current assets
€13.2m ▲ 35.7%
Equity and liabilities €16.0m
Equity
€2.4m ▲ 7.6%
Provisions
€903,000 ▲ 41.1%
Debt
€12.7m ▲ 23.8%
Debt's share of the balance-sheet total rises from 78.4% to 79.6%. Equity and debt are higher.
Key figures and ratios
EBITDA
€2.4m▲
2024 · €2.3m
Cash flow
€1.7m▲
2024 · €1.6m
Quick ratio
0.83▲
2024 · 0.56
Debt to equity
5.38▲
2024 · 4.68
ROE
49.4%▲
2024 · 47.5%
Interest coverage
18.84▲
2024 · 13.30
Debt ≤ 1 year
€11.8m▲
2024 · €9.8m
Income taxes
€483,070▲
2024 · €415,017
Staff costs
€7.0m▲
2024 · €6.0m
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Peer companies
Historical observationOf the 378 companies that looked in July 2024 the way this one looks now, 0.3% went bankrupt within 24 months and 97% are still going.
- Medium-sized
- 20 years or older
- solvency 10 to 30%
- a profit of 5% of the balance sheet or more
0.3%
went bankrupt
2.4%
stopped otherwise
97%
still going
For this company itself Checked computes a bankruptcy probability of 0.3% over twelve months; the group does not contradict it.
How reliable is this rule?
Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,338 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 1.0% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.9% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.
An observation about 378 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.
Annual accounts
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Operating income70/76A | €36.0m | €39.4m | €46.9m | €40.6m | €45.5m | ▲ 12.1% |
| Turnover70 | €32.9m | €36.1m | €42.1m | €39.9m | €43.4m | ▲ 8.8% |
| Change in stocks of work in progress, finished goods and contracts in progress71 | €236,190 | €64,306 | €1.8m | -€2.2m | -€1.3m | ▲ 43.5% |
| Other operating income74 | €2.8m | €3.2m | €3.0m | €2.9m | €3.3m | ▲ 13.9% |
| Non-recurring operating income76A | - | - | - | - | €36,374 | - |
| Operating charges60/66A | €34.5m | €38.1m | €44.7m | €38.9m | €43.7m | ▲ 12.2% |
| Goods for resale, raw materials and consumables60 | €23.4m | €26.2m | €31.9m | €25.2m | €28.8m | ▲ 14.0% |
| Purchases600/8 | €23.7m | €27.3m | €31.5m | €25.2m | €28.7m | ▲ 13.9% |
| Change in stocks: decrease (increase)609 | -€312,865 | -€1.1m | €426,394 | -€12,859 | €8,398 | ▲ 165% |
| Services and other goods61 | €4.8m | €5.5m | €5.8m | €6.4m | €7.2m | ▲ 11.4% |
| Remuneration, social security and pensions62 | €6.1m | €6.2m | €6.3m | €6.0m | €7.0m | ▲ 15.2% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €532,984 | €507,178 | €534,852 | €576,331 | €537,927 | ▼ 6.7% |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4 | €82,556 | €783 | -€32,455 | €1,327 | -€125,208 | ▼ 9,535% |
| Provisions for liabilities and charges: additions (uses and reversals)635/8 | -€520,939 | -€314,652 | €109,000 | €202,000 | €263,000 | ▲ 30.2% |
| Other operating charges640/8 | €69,954 | €73,504 | €82,683 | €140,736 | €93,769 | ▼ 33.4% |
| Non-recurring operating charges66A | - | - | - | €278,352 | €0 | ▼ 100% |
| Operating profit (loss)9901 | €1.4m | €1.3m | €2.2m | €1.7m | €1.9m | ▲ 10.1% |
| Financial income75/76B | €3,937 | €59,839 | €4,508 | €52,858 | €16,296 | ▼ 69.2% |
| Recurring financial income75 | €3,937 | €59,839 | €4,508 | €52,858 | €16,296 | ▼ 69.2% |
| Income from current assets751 | €0 | - | - | €48,308 | €0 | ▼ 100% |
| Other financial income752/9 | €3,937 | €59,839 | €4,508 | €4,550 | €16,296 | ▲ 258% |
| Financial charges65/66B | €136,468 | €247,563 | €314,165 | €294,511 | €237,823 | ▼ 19.2% |
| Recurring financial charges65 | €136,468 | €247,563 | €314,165 | €294,511 | €237,823 | ▼ 19.2% |
| Debt charges650 | €44,457 | €84,703 | €193,458 | €171,025 | €127,886 | ▼ 25.2% |
| Other financial charges652/9 | €92,010 | €162,860 | €120,707 | €123,487 | €109,937 | ▼ 11.0% |
| Profit (loss) for the period before taxes9903 | €1.3m | €1.1m | €1.9m | €1.5m | €1.6m | ▲ 13.2% |
| Income taxes67/77 | €371,433 | €308,901 | €533,408 | €415,017 | €483,070 | ▲ 16.4% |
| Taxes670/3 | €371,433 | €308,901 | €533,408 | €415,017 | €483,070 | ▲ 16.4% |
| Tax adjustments and reversals of tax provisions77 | €0 | - | - | - | - | - |
| Profit (loss) for the period9904 | €943,907 | €787,159 | €1.4m | €1.0m | €1.2m | ▲ 11.9% |
| Profit (loss) for the period to be appropriated9905 | €943,907 | €787,159 | €1.4m | €1.0m | €1.2m | ▲ 11.9% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total assets20/58 | €11.1m | €14.2m | €15.7m | €13.1m | €16.0m | ▲ 21.9% |
| Fixed assets21/28 | €2.9m | €3.2m | €3.4m | €3.4m | €2.7m | ▼ 18.3% |
| Intangible fixed assets21 | €17,312 | €10,194 | €70,089 | €46,123 | €3,870 | ▼ 91.6% |
| Tangible fixed assets22/27 | €2.9m | €3.2m | €3.3m | €3.3m | €2.7m | ▼ 17.3% |
| Land and buildings22 | €1.5m | €1.5m | €1.4m | €1.4m | €1.4m | ▼ 0.8% |
| Plant, machinery and equipment23 | €1.1m | €1.2m | €1.4m | €1.3m | €1.1m | ▼ 19.6% |
| Furniture and vehicles24 | €304,772 | €604,642 | €528,381 | €456,848 | €82,482 | ▼ 81.9% |
| Assets under construction and advance payments27 | - | - | - | €119,089 | €197,010 | ▲ 65.4% |
| Financial fixed assets28 | €6,000 | €6,000 | €6,000 | €6,000 | €6,000 | = |
| Other financial fixed assets284/8 | €6,000 | €6,000 | €6,000 | €6,000 | €6,000 | = |
| Amounts receivable and cash guarantees285/8 | €6,000 | €6,000 | €6,000 | €6,000 | €6,000 | = |
| Current assets29/58 | €8.1m | €11.0m | €12.3m | €9.8m | €13.2m | ▲ 35.7% |
| Stocks and contracts in progress3 | €4.0m | €5.2m | €6.5m | €4.3m | €3.5m | ▼ 18.3% |
| Stocks30/36 | €2.1m | €3.2m | €2.9m | €2.7m | €2.2m | ▼ 17.3% |
| Raw materials and consumables30/31 | €867,672 | €1.6m | €1.1m | €1.2m | €1.1m | ▼ 10.7% |
| Work in progress32 | €190,254 | €251,589 | €318,948 | €198,514 | €197,694 | ▼ 0.4% |
| Finished goods33 | €507,887 | €371,435 | €443,587 | €312,574 | €451,509 | ▲ 44.4% |
| Goods purchased for resale34 | €540,297 | €973,978 | €1.0m | €962,653 | €489,837 | ▼ 49.1% |
| Contracts in progress37 | €1.9m | €2.0m | €3.6m | €1.6m | €1.3m | ▼ 19.8% |
| Amounts receivable within one year40/41 | €4.1m | €5.5m | €5.3m | €5.2m | €9.2m | ▲ 76.7% |
| Trade receivables40 | €3.7m | €5.3m | €5.2m | €5.0m | €9.1m | ▲ 82.1% |
| Other amounts receivable41 | €362,331 | €221,792 | €90,041 | €223,953 | €125,340 | ▼ 44.0% |
| Cash at bank and in hand54/58 | €0 | €234,009 | €396,914 | €53,444 | €394,245 | ▲ 638% |
| Deferred charges and accrued income490/1 | €82,547 | €43,194 | €78,923 | €156,628 | €83,536 | ▼ 46.7% |
| Equity and liabilities | ||||||
| Total equity and liabilities10/49 | €11.1m | €14.2m | €15.7m | €13.1m | €16.0m | ▲ 21.9% |
| Equity10/15 | €993,186 | €1.3m | €1.9m | €2.2m | €2.4m | ▲ 7.6% |
| Contributions10/11 | €180,000 | €180,000 | €180,000 | €180,000 | €180,000 | = |
| Capital10 | €180,000 | €180,000 | €180,000 | €180,000 | €180,000 | = |
| Issued capital100 | €180,000 | €180,000 | €180,000 | €180,000 | €180,000 | = |
| Reserves13 | €18,000 | €18,000 | €18,000 | €18,000 | €18,000 | = |
| Non-distributable reserves130/1 | €18,000 | €18,000 | €18,000 | €18,000 | €18,000 | = |
| Legal reserve130 | €18,000 | €18,000 | €18,000 | €18,000 | €18,000 | = |
| Profit (loss) carried forward14 | €795,186 | €1.1m | €1.7m | €2.0m | €2.2m | ▲ 8.3% |
| Provisions and deferred taxes16 | €643,652 | €329,000 | €438,000 | €640,000 | €903,000 | ▲ 41.1% |
| Provisions for liabilities and charges160/5 | €643,652 | €329,000 | €438,000 | €640,000 | €903,000 | ▲ 41.1% |
| Other liabilities and charges164/5 | €643,652 | €329,000 | €438,000 | €640,000 | €903,000 | ▲ 41.1% |
| Amounts payable17/49 | €9.4m | €12.6m | €13.4m | €10.3m | €12.7m | ▲ 23.8% |
| Amounts payable within one year42/48 | €9.0m | €11.9m | €12.9m | €9.8m | €11.8m | ▲ 20.3% |
| Financial debts43 | €2.9m | €3.8m | €4.0m | €3.9m | €3.4m | ▼ 13.2% |
| Credit institutions430/8 | €56,289 | €0 | - | - | - | - |
| Other loans439 | €2.8m | €3.8m | €4.0m | €3.9m | €3.4m | ▼ 13.2% |
| Trade debts44 | €1.7m | €4.3m | €3.1m | €2.3m | €4.1m | ▲ 74.9% |
| Suppliers440/4 | €1.7m | €4.3m | €3.1m | €2.3m | €4.1m | ▲ 74.9% |
| Advances received on contracts in progress46 | €1.8m | €1.7m | €3.5m | €1.2m | €1.5m | ▲ 29.2% |
| Taxes, remuneration and social security45 | €1.7m | €1.5m | €1.5m | €1.6m | €1.7m | ▲ 9.0% |
| Taxes450/3 | €620,805 | €482,903 | €469,549 | €484,020 | €688,518 | ▲ 42.2% |
| Remuneration and social security454/9 | €1.1m | €998,226 | €1.1m | €1.1m | €1.0m | ▼ 5.5% |
| Other amounts payable47/48 | €900,000 | €500,000 | €750,000 | €750,000 | €1.0m | ▲ 33.3% |
| Accrued charges and deferred income492/3 | €448,930 | €734,229 | €478,225 | €504,516 | €965,413 | ▲ 91.4% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €943,907 | €787,159 | €1.4m | €1.0m | €1.2m | ▲ 11.9% |
| + Depreciation and write-downs630 | €532,984 | €507,178 | €534,852 | €576,331 | €537,927 | ▼ 6.7% |
| Operating cash flow (approximation) | €1.5m | €1.3m | €1.9m | €1.6m | €1.7m | ▲ 5.3% |
| Investment in fixed assets (approximation) | - | -€819,116 | -€674,917 | -€546,333 | €75,996 | ▲ 114% |
| Change in cash | - | €234,009 | €162,905 | -€343,470 | €340,800 | ▲ 199% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
31-08
State Gazette act
Resignations: VAN DIJK Geert, VAN dE VOORDE Kathleen Julia René and 2 othersReappointments: VAN DIJK Geert, VAN dE VOORDE Kathleen Julia René and 2 others · Statutes amendment · Capital22 facts ▸
State Gazette act
Resignations: VAN DIJK Geert, VAN dE VOORDE Kathleen Julia René and 2 others
Reappointments: VAN DIJK Geert, VAN dE VOORDE Kathleen Julia René and 2 others · Statutes amendment · Capital22 facts ▸
- General meeting, 16-07-2026
- Statutes amendment
- Statutes amendment
- Capital, €180.000
- Registered office clause, Industriepark 10, 9031 Gent, Drongen
- Director resignation, VAN DIJK Geert (director)
- Director resignation, VAN dE VOORDE Kathleen Julia René (director)
- Director resignation, DRAKE Tony Anthony (director)
- Director resignation, dE JUST Erwin Willem (director)
- Director discharge, VAN DIJK Geert
- Director discharge, VAN dE VOORDE Kathleen Julia René
- Director discharge, DRAKE Tony Anthony
- +10 further facts in this act
10-07
NBB filing
Annual accounts filed
fiscal year 2025 · full schema
23-06
State Gazette act
Resignation: Barbara van Driessche (director)6 facts ▸
State Gazette act
Resignation: Barbara van Driessche (director)
6 facts ▸
- General meeting, 25-03-2026
- Director resignation, Barbara van Driessche (director)
- Board composition, Geert-Jacob van Dijk (director)
- Board composition, Kathleen Van de Voorde (director)
- Board composition, Tony Drake (director)
- Board composition, Erwin De Just (director)
2025
25-06
NBB filing
Annual accounts filed
fiscal year 2024 · full schema
2024
31-12
Financial
Equity above €2mEq €2.2m ▲15.3%
7 profitable years in a row build equity to €2.2m.
04-06
NBB filing
Annual accounts filed
fiscal year 2023 · full schema
2023
31-12
Financial
Highest result since 2018net €1.4m ▲74.5%
Operating result €2.2m, net result €1.4m, both a record.
16-05
NBB filing
Annual accounts filed
fiscal year 2022 · full schema
2022
31-12
Financial
Equity above €1mEq €1.3m ▲28.9%
5 profitable years in a row build equity to €1.3m.
18-05
NBB filing
Annual accounts filed
fiscal year 2021 · full schema
2021
20-05
NBB filing
Annual accounts filed
fiscal year 2020 · full schema
2020
03-06
NBB filing
Annual accounts filed
fiscal year 2019 · full schema
Show earlier events
2019
14-06
NBB filing
Annual accounts filed
fiscal year 2018 · full schema
2018
12-07
NBB filing
Annual accounts filed
fiscal year 2017 · full schema
2017
14-06
NBB filing
Annual accounts filed
fiscal year 2016 · full schema
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
2 of 17 acts read
About the unread acts
Of the 17 Belgian State Gazette acts we know for this company, 2 have been read. The other 15 have not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
under verification, last change in 2026
This board is reconstructed from a single act (26356971). A Gazette act generally publishes only CHANGES, not a full roll call, so directors unchanged since then may be missing here. The KBO register holds the complete list of function holders.
dE JUST Erwin Willem
CurrentNon-statutory director
DRAKE Tony Anthony
CurrentNon-statutory director
VAN dE VOORDE Kathleen Julia René
CurrentNon-statutory director
VAN DIJK Geert
CurrentNon-statutory director
Derived from published Gazette acts. The CBE keeps the official list of function holders; we do not read it, so the two can differ.
See the function holders in the CBE →
Not every act has been read: a resignation may be missing here
15 of this company's 17 Belgian State Gazette acts have not been read yet. Appointments and resignations recorded in them are missing above: a director who resigned there may therefore still show here as sitting. The acts are in the Timeline.
Location & real-estate footprint
Registered office, Gent · 2 establishment units since 1985
Ground area
1.8 ha
Building footprint
6,743 m²
Volume, LiDAR
106 m³
2 parcels, Flanders · tallest building 17.3 m. Linked by address, not a title deed.
2 establishment units
Industriepark-Drongen 10, 9031 Gent
since 19852.027.542.401
Melktechniek West-Vlaanderen
since 20232.361.616.834
2 parcels
Flanders
2
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 44017D0845/00F000 | Flanders | 1.7 ha | 1 · 6,370 m² | - |
| 37012D0171/00Y000 | Flanders | 1,076 m² | 1 · 373 m² | 17.3 m |
Linked by address, not proof of ownership
Good to know
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Mandate history
5 people since 2026, 4 in office
- Board
- began earlier
| Name | Functions and periods |
|---|---|
| dE JUST Erwin Willem |
|
| DRAKE Tony Anthony |
|
| VAN dE VOORDE Kathleen Julia René |
|
| VAN DIJK Geert |
|
| Barbara van Driessche |
|
Articles of association
Who signs
Two directors jointly
Annual meeting
“4. De raad van bestuur mag bijzondere volmachten verlenen aan één of meer personen. De vennootschap wordt geldig vertegenwoordigd door deze bijzondere volmachtdragers binnen de grenzen van hun volmacht, onverminderd de verantwoordelijkheid van de raad van bestuur in geval van overdreven volmacht.…”
Full text
4. De raad van bestuur mag bijzondere volmachten verlenen aan één of meer personen. De vennootschap wordt geldig vertegenwoordigd door deze bijzondere volmachtdragers binnen de grenzen van hun volmacht, onverminderd de verantwoordelijkheid van de raad van bestuur in geval van overdreven volmacht. 12.9 Vergoeding van de bestuurders Het mandaat van bestuurder wordt niet bezoldigd behoudens andersluidende beslissing van de algemene vergadering. Algemene vergadering - Organisatie en bijeenroeping De gewone algemene vergadering wordt jaarlijks gehouden op de vijftiende dag van de maand mei om veertien uur. Indien die dag een wettelijke feestdag of een zondag is, heeft de vergadering plaats op de eerstvolgende werkdag. De gewone, bijzondere en buitengewone algemene vergaderingen worden gehouden op de zetel van de vennootschap of op elke andere plaats vermeld in de oproeping. De oproepingen tot een algemene vergadering vermelden de agenda en worden tenminste vijftien (15) dagen voor de algemene vergadering verstuurd per e-mail. Voor de personen waarvoor de vennootschap niet over een e-mailadres beschikt, worden de oproepingen verstuurd per gewone post gelijktijdig met de verzending van de oproepingen per e-mail.
Purpose
De vervaardiging,invoer,aankoop,behandeling,verdeling,uitvoer en verkoop van dierengeneeskundige en farmaceutische producten voor dieren,dierenvoeders,toevoegingen voor…
Full purpose (3 activities)
- De vervaardiging,invoer,aankoop,behandeling,verdeling,uitvoer en verkoop van dierengeneeskundige en farmaceutische producten voor dieren,dierenvoeders,toevoegingen voor voeders,producten met betrekking tot de gezondheid van dieren,en alle andere producten,chemische zowel als andere,bedoeld voor niet-menselijke consumptie alsmede alle producten met betrekking tot de vervaardiging,behandeling,kwaliteit en bewaring van voedingsmiddelen en melkproducten voor menselijk gebruik.
- De vervaardiging,ontwikkeling en verkoop van alle uitrusting met betrekking tot deze producten.
- De vervaardiging,invoer,aankoop,ontwikkeling,verdeling,uitvoer en verkoop van de apparatuur en producten bestemd voor de veehouderij.
Name clause
Legal form clause
Naamloze vennootschap
Registered office clause
One provision in the deed
Board rule
12.1 Samenstelling raad van bestuur, hoogstens zes jaar
Bevoegdheden raad van bestuur, alle handelingen nodig of dienstig voor verwezenlijking voorwerp
Other statement
Raad kiest voorzitter uit midden, 12.2 Voorzitterschap raad van bestuur
Plaats in oproeping,bij gebrek zetel vennootschap, 12.3 Bijeenroeping raad van bestuur
Elke bestuurder kan schriftelijke volmacht aan collega voor bepaalde raad met stem,lastgever geacht aanwezig, 12.4 Besluitvorming raad van bestuur
12.5 Notulen raad van bestuur, voorzitter,gedelegeerd-bestuurder of ten minste twee bestuurders
Binnen dagelijks bestuur alleen optreden, dagelijks bestuur
Vergoeding bestuurders, andersluidende beslissing algemene vergadering
Oproeping algemene vergadering, gewone post voor personen zonder e-mailadres gelijktijdig
Voorzitter raad van bestuur, samenstelling bureau
Beraadslaging
Bestemming winst, één tiende van kapitaal
1 more provision on this in the deed
Structure & network
Owners and holdings
2 ownersOwners 2
- DeLaval Holding BVNLparentSourceown accounts 202599.99%
- DeLaval Holding ABSESourceown accounts 20250.01%
Holdings 0
The accounts to 31-12-2025 list no holdings, and no other source names one.
According to the 2025 annual accounts of DELAVAL and those of the other companies, the acts in the Belgian Gazette and the LEI register. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.
Connections & network
4 current directorsThe network starts from this company’s directors. Other companies they run appear here as nodes.
This company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, scroll to zoom.
Capital and shareholders
Capital over the years
- 31-08-2026 Capital stated in the act · 180,000 EUR · 7,250 shares
Public money · subsidies and aid
Flemish government
2022 to 2025 · 7 entries · 11,694 EUR awarded · 9,974 EUR paid| Year | Entries | awarded | paid |
|---|---|---|---|
| 2025 | 1 | 281 EUR | 281 EUR |
| 2024 | 1 | 841 EUR | 841 EUR |
| 2023 | 2 | 2,300 EUR | 3,260 EUR |
| 2022 | 3 | 8,272 EUR | 5,592 EUR |
Recognitions · licences · registrations
Dual-learning approval
7 live approvalsElektromecanicien (vwo)
Elektromecanicien duaal (so)
Elektromechanische technieken duaal (so)
Onderhoudsmonteur (vwo)
Preventief onderhoud machines en installaties duaal (so)
Technieker industriële procesautomatisatie (vwo)
Show 1 more
Technieker industriële procesautomatisatie duaal (so)
Similar companies · same sector, comparable size
remedent
BE 0474.973.168
Gent · Eq €2.3m
MONDOMED
BE 0449.866.303
Hamont-Achel · Eq €2.5m
LABORATOIRES LOHMANN & RAUSCHER
BE 0402.437.261
Liège · Eq €2.0m
Phoenix Biosciences
BE 1027.640.071
Nivelles · Eq €3.7m
MEDI - LINE
BE 0452.084.633
Liège · Eq €3.8m
Of 97 companies in sector 21209 we hold annual accounts for 74. 42 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Identification & contact
Identification
Legal formPublic limited company
Founded15-07-1985
Fiscal year end31-12
Activities, NACEBEL 2025
21209Manufacture of basic pharmaceutical products and pharmaceutical preparations
46610Wholesale trade
28300Manufacture of machinery and equipment not elsewhere classified
Contact
E-mail
info@mtwv.beWingene
Phone
053460487Wingene
E-invoicing
Reachable via Peppol
Peppol ID
0208:0427530468
If you follow this company, Checked tells you the day it leaves the Peppol register.
Register as of 28 September 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.